Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Oropharnx Cancer

Trial Name: A Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer.

Protocol ID: RTOG 1016


  • Must have pathologically proven diagnosis of squamous cell carcinoma of the oropharynx.
  • Must be > 18 years of age.
  • Must meet required laboratory values.
  • Must not be pregnant.
  • Women of childbearing potential or sexually active males, must use effective contraception throughout their participation in the treatment phase of the study and at least 6 months following the last study treatment.
  • No prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years.
  • No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
  • No prior allergic reaction to cisplatin or cetuximab.

No prior cetuximab or other anti-EGFR therapy.

Enrollment: • About 706 people will take part in this study at several medical centers.


Taking part in this study may or may not make your health better. While doctors hope radiation therapy with cetuximab will be as effective in keeping your head and neck cancer from growing as radiation therapy and cisplatin with less severe side effects, there is no proof of this yet. The effects of a combination of radiation and cetuximab may be no different or worse than radiation and cisplatin. We do know that the information from this study will help doctors learn more about these therapies as a treatment for head and neck cancer that is HPV positive. This information could help future cancer patients.


These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.

Created: Dec 1, 2011

Updated: May 21, 2014

« Return to Trials